This page contains a Flash digital edition of a book.
Neurodegenerative Disease Parkinson’s Disease


1. Kessler II, Epidemiologic studies of Parkinson's disease. 3. A community-based survey, Am J Epidemiol, 1972;96:242–54.


2. Dorsey ER, Constantinescu R, Thompson JP, et al., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 2007;68:384–6.


3. Lang AE, Lozano AM, Parkinson's disease. Second of two parts, N Engl J Med, 1998;339:1130–43.


4. Forno LS, Neuropathology of Parkinson's disease, J Neuropathol Exp Neurol, 1996;55:259–72.


5. Breydo L, Uversky VN, Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases, Metallomics, 2011;3:1163–80.


6. Snyder H, Mensah K, Theisler C, et al., Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function, J Biol Chem, 2003;278:11753–9.


7. Braak H, Ghebremedhin E, Rub U, et al., Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res, 2004;318:121–34.


8. Schapira AH, Mann VM, Cooper JM, et al., Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease, J Neurochem, 1990;55:2142–5.


9. Abou-Sleiman PM, Muqit MM, Wood NW, Expanding insights of mitochondrial dysfunction in Parkinson's disease, Nat Rev Neurosci, 2006;7:207–19.


10. Moore DJ, Zhang L, Troncoso J, et al., Molecular pathophysiology of Parkinson's disease, Annu Rev Neurosci, 2005;28:57–87.


11. Zhang L, Shimoji M, Thomas B, et al., Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis, Hum Mol Genet, 2005;14:2063–73.


12. Betarbet R, Sherer TB, MacKenzie G, et al., Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat Neurosci, 2000;3:1301–6.


13. Sherer TB, Betarbet R, Testa CM, et al., Mechanism of toxicity in rotenone models of Parkinson's disease, J Neurosci, 2003;23:10756–64.


14. Hart RG, Pearce LA, Ravina BM, et al., Neuroprotection trials in Parkinson's disease: systematic review, Mov Disord, 2009;24:647–54.


15. Parkinson Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, N Engl J Med, 1993;328:176–83.


16. Jankovic J, Hunter C, A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease, Parkinsonism Relat Disord, 2002;8:271–6.


17. Parkinson Study Group, Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression, Jama, 2002;287:1653–61.


18. Parkinson Study Group, A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease, Arch Neuro, 2004;61:561–6.


19. Fahn S, Oakes D, Shoulson I, et al., Levodopa and the progression of Parkinson's disease, N Engl J Med, 2004;351:2498–508.


20. Whone AL, Watts RL, Stoessel AJ, et al., Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study, Ann Neurol, 2003:54:93–101.


21. Shults CW, Oakes D, Kieburtz K, et al., Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline, Arch Neurol, 2002;59:1541–50.


22. NINDS NET-PD Investigators, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease, Neurology, 2006;66:664–71.


23. NINDS NET-PD Investigators, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease, Neurology, 2007:68:20–8.


24. Chan CS, Guzman JN, Illijic E, et al., 'Rejuvenation' protects neurons in mouse models of Parkinson's disease, Nature, 2007;447:1081–6.


25. Guzman JN, Sanchez-Padilla J, Wokosin D, et al., Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1, Nature, 2010;468:696–700.


26. Nedergaard M, Hansen AJ, Characterization of cortical depolarizations evoked in focal cerebral ischemia, J Cereb Blood Flow Metab, 1993;13:568–74.


27. Puopolo A, Boice JA, Fidelholtz JL. et al., A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis, Osteoarthritis Cartilage, 2007;15: 1348–56.


28. Khaliq ZM, Bean BP, Sonsalla PK, Brooks BA, Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances, J Neurosci, 2010;30:7401–13.


29. German DC, Manave KF, Sonsalla PK, Brooks BA, Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k- containing cells, Ann N Y Acad Sci, 1992;648:42–62.


30. Nicholls DG, Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease, Int J Biochem Cell Biol, 2002;34:1372–81.


31. Schapira AH, Mitochondrial pathology in Parkinson's disease, Mt Sinai J Med, 2011;78:872–81.


32. Ilijic E, Guzman JN, Surmeier DJ, The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease, Neurobiol Dis, 2011;43:364–71.


33. Sah P, McLachlan EM, Differences in electrophysiological properties between neurones of the dorsal motor nucleus of the vagus in rat and guinea pig, J Auton Nerv Syst, 1993;42:89–98.


34. Burlhis TM, Aghajanian GK, Pacemaker potentials of serotonergic dorsal raphe neurons: contribution of a low-threshold Ca2+ conductance, Synapse, 1987;1:582–8.


35. Takakusaki K, Kitai ST, Ionic mechanisms involved in the spontaneous firing of tegmental pedunculopontine nucleus neurons of the rat, Neuroscience, 1997;78:771–94.


36. Taddese A, Bean BP, Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons, Neuron, 2002;33:587–600.


37. Puopolo M, Bean BP, Raviola E, Spontaneous activity of isolated dopaminergic periglomerular cells of the main olfactory bulb, J Neurophysiol, 2005;94:3618–27.


38. Williams JT, Christie MJ, North RA, Roques BP, Potentiation of enkephalin action by peptidase inhibitors in rat locus ceruleus in vitro, J Pharmacol Exp Ther, 1987;243:397–401.


39. Becker C, Jick SS, Meier CR, Use of antihypertensives and the risk of Parkinson disease, Neurology, 2008;70:1438–44.


40. Ritz B, Rhodes SL, Qian L, et al., L-type calcium channel blockers and Parkinson disease in Denmark, Ann Neurol, 2010;67:600–6.


41. Drugs Information Online, Isradipine, 2007. Available at: www.drugs.com/pro/isradipine.html (accessed December 12, 2011).


42. Kupsch A, Sautter J, Schwarz J, et al., 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level, Brain Res, 1996;741:185–96.


43. Simuni T, Borushko E, Avram MJ, et al., Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study, Mov Disord, 2010;25: 2863–6.


44. Simuni T, Oakes D, Surmeier DJ, STEADY-PD: Interim tolerability data analysis Movement disorders 2011, Presented at: 15th MDS International Congress, Toronto, June 5–9, 2011.


112


US NEUROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108